Implementation Science (Aug 2023)

Reporting of costs and economic impacts in randomized trials of de-implementation interventions for low-value care: a systematic scoping review

  • Petra Falkenbach,
  • Aleksi J. Raudasoja,
  • Robin W. M. Vernooij,
  • Jussi M. J. Mustonen,
  • Arnav Agarwal,
  • Yoshitaka Aoki,
  • Marco H. Blanker,
  • Rufus Cartwright,
  • Herney A. Garcia-Perdomo,
  • Tuomas P. Kilpeläinen,
  • Olli Lainiala,
  • Tiina Lamberg,
  • Olli P. O. Nevalainen,
  • Eero Raittio,
  • Patrick O. Richard,
  • Philippe D. Violette,
  • Kari A. O. Tikkinen,
  • Raija Sipilä,
  • Miia Turpeinen,
  • Jorma Komulainen

DOI
https://doi.org/10.1186/s13012-023-01290-3
Journal volume & issue
Vol. 18, no. 1
pp. 1 – 13

Abstract

Read online

Abstract Background De-implementation of low-value care can increase health care sustainability. We evaluated the reporting of direct costs of de-implementation and subsequent change (increase or decrease) in health care costs in randomized trials of de-implementation research. Methods We searched MEDLINE and Scopus databases without any language restrictions up to May 2021. We conducted study screening and data extraction independently and in duplicate. We extracted information related to study characteristics, types and characteristics of interventions, de-implementation costs, and impacts on health care costs. We assessed risk of bias using a modified Cochrane risk-of-bias tool. Results We screened 10,733 articles, with 227 studies meeting the inclusion criteria, of which 50 included information on direct cost of de-implementation or impact of de-implementation on health care costs. Studies were mostly conducted in North America (36%) or Europe (32%) and in the primary care context (70%). The most common practice of interest was reduction in the use of antibiotics or other medications (74%). Most studies used education strategies (meetings, materials) (64%). Studies used either a single strategy (52%) or were multifaceted (48%). Of the 227 eligible studies, 18 (8%) reported on direct costs of the used de-implementation strategy; of which, 13 reported total costs, and 12 reported per unit costs (7 reported both). The costs of de-implementation strategies varied considerably. Of the 227 eligible studies, 43 (19%) reported on impact of de-implementation on health care costs. Health care costs decreased in 27 studies (63%), increased in 2 (5%), and were unchanged in 14 (33%). Conclusion De-implementation randomized controlled trials typically did not report direct costs of the de-implementation strategies (92%) or the impacts of de-implementation on health care costs (81%). Lack of cost information may limit the value of de-implementation trials to decision-makers. Trial registration OSF (Open Science Framework): https://osf.io/ueq32 .

Keywords